Mixed vs full donor engraftment early after hematopoietic cell transplant: Impact on incidence and control of cytomegalovirus infection

Research output: Contribution to journalArticle

Abstract

Recovery of cytomegalovirus (CMV)-specific immunity after hematopoietic cell transplantation (HCT) is essential in controlling CMV infection. We hypothesize that mixed donor engraftment as measured by chimerism at day 30 in CMV D(+) HCTs and full chimerism in CMV D(−) HCTs will be predictive of CMV reactivation. Prospectively collected data for 407 CMV R+ HCT recipients transplanted from 2006 to 2014 at the University of Minnesota were retrospectively analyzed. Full and mixed donor engraftment were defined as ≥95% or <95% donor cells at day 30, respectively. Source of engraftment determination included preferentially peripheral blood CD3 fraction, then myeloid cell fraction (CD15+), then bone marrow. In 407 CMV R+ subjects, 77% (n = 313) were CMV D(−) cells from umbilical cord blood (n = 209), peripheral blood (n = 58) or marrow (n = 46). Fifty three per cent received reduced intensity conditioning (RIC). At day +30, full donor engraftment was seen in 82% of myeloablative and 55% of RIC transplants. The cumulative incidence of CMV infection 1-year after transplant was not different in patients with full (54%, n = 276) or mixed (53%, n = 131) donor engraftment. Control of CMV did not significantly differ among the two groups. In multiple regression analysis, there was no significant association between donor engraftment (mixed or full) and incidence or control of CMV.

Original languageEnglish (US)
Article numbere13070
JournalTransplant Infectious Disease
Volume21
Issue number3
DOIs
StatePublished - Jun 1 2019

Fingerprint

Cytomegalovirus Infections
Cytomegalovirus
Tissue Donors
Transplants
Incidence
Chimerism
Cell Transplantation
Bone Marrow
Somatostatin-Secreting Cells
Myeloid Cells
Fetal Blood
Immunity
Regression Analysis

Keywords

  • chimerism
  • cytomegalovirus
  • donor engraftment
  • stem cell transplant

PubMed: MeSH publication types

  • Journal Article

Cite this

@article{8c5c6a6144de4e9d99dc93e602446667,
title = "Mixed vs full donor engraftment early after hematopoietic cell transplant: Impact on incidence and control of cytomegalovirus infection",
abstract = "Recovery of cytomegalovirus (CMV)-specific immunity after hematopoietic cell transplantation (HCT) is essential in controlling CMV infection. We hypothesize that mixed donor engraftment as measured by chimerism at day 30 in CMV D(+) HCTs and full chimerism in CMV D(−) HCTs will be predictive of CMV reactivation. Prospectively collected data for 407 CMV R+ HCT recipients transplanted from 2006 to 2014 at the University of Minnesota were retrospectively analyzed. Full and mixed donor engraftment were defined as ≥95{\%} or <95{\%} donor cells at day 30, respectively. Source of engraftment determination included preferentially peripheral blood CD3 fraction, then myeloid cell fraction (CD15+), then bone marrow. In 407 CMV R+ subjects, 77{\%} (n = 313) were CMV D(−) cells from umbilical cord blood (n = 209), peripheral blood (n = 58) or marrow (n = 46). Fifty three per cent received reduced intensity conditioning (RIC). At day +30, full donor engraftment was seen in 82{\%} of myeloablative and 55{\%} of RIC transplants. The cumulative incidence of CMV infection 1-year after transplant was not different in patients with full (54{\%}, n = 276) or mixed (53{\%}, n = 131) donor engraftment. Control of CMV did not significantly differ among the two groups. In multiple regression analysis, there was no significant association between donor engraftment (mixed or full) and incidence or control of CMV.",
keywords = "chimerism, cytomegalovirus, donor engraftment, stem cell transplant",
author = "Green, {Jaime S} and Shanley, {Ryan M} and Brunstein, {Claudio G} and Young, {Jo-Anne H} and Verneris, {Michael R}",
year = "2019",
month = "6",
day = "1",
doi = "10.1111/tid.13070",
language = "English (US)",
volume = "21",
journal = "Transplant Infectious Disease",
issn = "1398-2273",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Mixed vs full donor engraftment early after hematopoietic cell transplant

T2 - Impact on incidence and control of cytomegalovirus infection

AU - Green, Jaime S

AU - Shanley, Ryan M

AU - Brunstein, Claudio G

AU - Young, Jo-Anne H

AU - Verneris, Michael R

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Recovery of cytomegalovirus (CMV)-specific immunity after hematopoietic cell transplantation (HCT) is essential in controlling CMV infection. We hypothesize that mixed donor engraftment as measured by chimerism at day 30 in CMV D(+) HCTs and full chimerism in CMV D(−) HCTs will be predictive of CMV reactivation. Prospectively collected data for 407 CMV R+ HCT recipients transplanted from 2006 to 2014 at the University of Minnesota were retrospectively analyzed. Full and mixed donor engraftment were defined as ≥95% or <95% donor cells at day 30, respectively. Source of engraftment determination included preferentially peripheral blood CD3 fraction, then myeloid cell fraction (CD15+), then bone marrow. In 407 CMV R+ subjects, 77% (n = 313) were CMV D(−) cells from umbilical cord blood (n = 209), peripheral blood (n = 58) or marrow (n = 46). Fifty three per cent received reduced intensity conditioning (RIC). At day +30, full donor engraftment was seen in 82% of myeloablative and 55% of RIC transplants. The cumulative incidence of CMV infection 1-year after transplant was not different in patients with full (54%, n = 276) or mixed (53%, n = 131) donor engraftment. Control of CMV did not significantly differ among the two groups. In multiple regression analysis, there was no significant association between donor engraftment (mixed or full) and incidence or control of CMV.

AB - Recovery of cytomegalovirus (CMV)-specific immunity after hematopoietic cell transplantation (HCT) is essential in controlling CMV infection. We hypothesize that mixed donor engraftment as measured by chimerism at day 30 in CMV D(+) HCTs and full chimerism in CMV D(−) HCTs will be predictive of CMV reactivation. Prospectively collected data for 407 CMV R+ HCT recipients transplanted from 2006 to 2014 at the University of Minnesota were retrospectively analyzed. Full and mixed donor engraftment were defined as ≥95% or <95% donor cells at day 30, respectively. Source of engraftment determination included preferentially peripheral blood CD3 fraction, then myeloid cell fraction (CD15+), then bone marrow. In 407 CMV R+ subjects, 77% (n = 313) were CMV D(−) cells from umbilical cord blood (n = 209), peripheral blood (n = 58) or marrow (n = 46). Fifty three per cent received reduced intensity conditioning (RIC). At day +30, full donor engraftment was seen in 82% of myeloablative and 55% of RIC transplants. The cumulative incidence of CMV infection 1-year after transplant was not different in patients with full (54%, n = 276) or mixed (53%, n = 131) donor engraftment. Control of CMV did not significantly differ among the two groups. In multiple regression analysis, there was no significant association between donor engraftment (mixed or full) and incidence or control of CMV.

KW - chimerism

KW - cytomegalovirus

KW - donor engraftment

KW - stem cell transplant

UR - http://www.scopus.com/inward/record.url?scp=85063647548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063647548&partnerID=8YFLogxK

U2 - 10.1111/tid.13070

DO - 10.1111/tid.13070

M3 - Article

C2 - 30864271

AN - SCOPUS:85063647548

VL - 21

JO - Transplant Infectious Disease

JF - Transplant Infectious Disease

SN - 1398-2273

IS - 3

M1 - e13070

ER -